BIOMAT Database Logo BIOMAT Database Logo

Cinnarizine-induced parkinsonism: ten years later. 1999

A Negrotti, and S Calzetti

UI MeSH Term Description Entries
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002936 Cinnarizine A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS. 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine,Cinarizina Inkey,Cinarizina Ratiopharm,Cinarizine,Cinazière,Cinna,Cinnarizin AL,Cinnarizin Siegfried,Cinnarizin Von Ct,Cinnarizin-Ratiopharm,Cinnarizine L-Tartrate,Cinnarizine L-Tartrate (1:1),Cinnarizine, (E)-Isomer,Cinnarizine, Dihydrochloride,Cinnipirine,Cisaken,Dimitronal,R-516,Stugeron,Stugeron Forte,Cinnarizin Ratiopharm,Cinnarizine L Tartrate,Dihydrochloride Cinnarizine,L-Tartrate, Cinnarizine,R 516,R516,Von Ct, Cinnarizin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Negrotti, and S Calzetti
Cinnarizine-induced parkinsonism: ten years later.
May 1998, Movement disorders : official journal of the Movement Disorder Society,
A Negrotti, and S Calzetti
Cinnarizine-induced parkinsonism in primates.
April 1992, Clinical neuropharmacology,
A Negrotti, and S Calzetti
Ten years later.
January 1977, Journal of allied health,
A Negrotti, and S Calzetti
Ten years later.
August 1992, RN,
A Negrotti, and S Calzetti
Ten years later.
October 2014, The journal of sexual medicine,
A Negrotti, and S Calzetti
Ten years later...
March 2009, Journal of cell communication and signaling,
A Negrotti, and S Calzetti
Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza's syndrome.
September 2009, Arquivos de neuro-psiquiatria,
A Negrotti, and S Calzetti
Dobutamine: ten years later.
January 1989, Pharmacotherapy,
A Negrotti, and S Calzetti
Mifepristone: ten years later.
January 2010, Contraception,
A Negrotti, and S Calzetti
Scabies, ten years later.
January 1966, Archives of dermatology,
Copied contents to your clipboard!